CURE

Fewer Lymph Node Biopsies for Older Women With Early Breast Cancer

Fewer older women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer are undergoing routine sentinel lymph node biopsy (SLNB), according to data that were presented at the ...
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The Manila Times

Registrational Phase III AMPLIFY trial: Target number of participants achieved

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
The Straits Times

Inside the brain’s night shift: Sleep research on biological ‘wash cycle’ shows promise

SINGAPORE – The 2026 World Sleep Day treats sleep as seriously as diet and exercise with its new “sleep well, live better” theme. The rallying call is built around a simple premise: Sleep is not a ...
European Medical Journal

Half-Dose Gadopiclenol Enhances Breast MRI Contrast

Half-dose gadopiclenol provides equal or better breast MRI contrast than full-dose gadobutrol. Find out how it could reduce ...

New tracking tool reveals how T cells adapt in different organs

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a game plan, and coordinate their defenses in lymphoid organs. Researchers have ...

Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines ...

College Student, Who Thought She Had a UTI, Diagnosed with Rare Disease: ‘I Was Mad at the World for a Long Time’

After weeks of doctor visits and her condition worsening, Emma Operacz was given an unexpected diagnosis ...

Everything You Need To Know About Breast Cancer And Medicare

A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare ...

Castle Biosciences, Inc.: DecisionDx-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to ...

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (S ...